The primary results from its Phase 3 trial REVEAL, which was the largest Phase 3 trial for CETP inhibition to date, were published in 2017.58 REVEAL was a randomized, double-blind, placebo-controlled trial in 30 449 participants with ASCVD with a mean of 4.1 years follow-up, which compared anacetrapib 100 mg once daily to placebo. This evidence concerns the gene CETP and atherosclerosis.